YOKOHAMA, Japan, Dec. 05, 2016 -- Silvaco Japan Co., Ltd. (Silvaco) announced that the Takeya Lab at Graduate School of Frontier Sciences, The University of Tokyo, has selected Silvaco’s Utmost IV for HiSIM-Organic SPICE model parameter extraction which can be used in circuit simulation. HiSIM-Organic is the newest SPICE model for organic semiconductor device, based on surface potential, announced by Professor Miura’s group at the HiSIM Research Center, Hiroshima University.
The Takeya Lab is conducting research on diverse organic electronics ranging from foundational chemical and physical research to industrial applications. These applications are centered on flexible and low-cost organic semiconductor devices that are expected to become next generation electronic materials. The Takeya Lab is highly regarded in the field of printed organic semiconductor devices and is one of the world’s leading research labs due to its wide-ranging, advanced level research.
The Takeya Lab is working to apply the essential HiSIM-Organic SPICE model to circuit simulation to support their design research on high-performance organic semiconductor device circuits. The lab chose Silvaco’s Utmost IV on the basis of the results obtained on actual measurement data. Utmost IV provides a flexible yet robust parameter extraction environment for the HiSIM-Organic models. By applying this HiSIM-Organic model, Takeya Lab plans to obtain characteristics closer to an actual device than can be achieved with conventional models.
Silvaco’s Utmost IV is a SPICE modeling tool used to extract and optimize SPICE model parameters. Utmost IV is used by numerous customers and supports many models, particularly early support for the HiSIM model series and TFT devices. Customers appreciate its easy-to-use interface and flexibility.
Professor Junichi Takeya of the Takeya Lab stated, “A concern of our lab was how quickly parameter extraction could be done in the HiSIM-Organic model announced by Professor Miura’s group at Hiroshima University. We were able to confirm that Silvaco’s Utmost IV tool is fast, shows good convergence, and is extremely useful in the extraction of HiSIM-Organic model parameters.”
Silvaco’s General Manager, Yoshiharu Furui, stated, “Currently, organic semiconductor devices are attracting a high level of attention from various markets, and providing the most accurate simulation environment is a major role for Silvaco.
"We are greatly encouraged that Utmost IV is able to contribute to HiSIM-Organic model use in the distinguished Takeya Lab.”
About Silvaco Japan Co., Ltd.
Silvaco Japan was first established as a Japanese branch of Silvaco, Inc. in 1989 and incorporated as a Japanese corporation in 1995. Silvaco Japan's corporate mission is to be the leading provider of TCAD and EDA software products in the Japanese market. To achieve and maintain its leadership objective, Silvaco Japan is focused on building and growing a strong sales, product support and R&D work force. Silvaco Japan is headquartered at the Landmark Tower in Yokohama, and maintains an additional office in Kyoto.
PRESS/MEDIA CONTACT: [email protected]


Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Italy Fines Apple €98.6 Million Over App Store Dominance
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 



